Bayer Chief Dekkers Departs With Words Of Warning, Wisdom For Pharma
This article was originally published in Scrip
Executive Summary
Bayer AG, which is embarking on a new journey as a "pure" life science business with a fresh captain ready to take the helm for fiscal 2016, kept its focus on innovation during its annual results presentation in Leverkusen, Germany. But departing chief Dr. Marijn Dekkers had a few concerns to share with the wider industry before he grabs his coat.
You may also be interested in...
2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie
GSK, Bayer, Celgene, Amgen, AstraZeneca, Bristol-Myers Squibb, Sanofi, Merck & Co and AbbVie are among the pharma companies due to report second-quarter results imminently. As the financial reporting season moves into a second week, Scrip takes a look at the key things to watch for.
Bayer Thins R&D Pipeline, Backs Finerenone In Kidney But Not Heart Disease
Germany’s leading pharmaceutical company Bayer has taken future competition into account when stopping the Phase III development of finerenone for congestive heart failure, and targeting specific CHF patients for treatment with another potential cardiovascular, vericiguat.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.